NEW YORK--(BUSINESS WIRE) October 22, 2024 -- Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved...
Vous n'êtes pas connecté
Needle free biotechnology company Vaxxas has announced that the United States National Institutes of Health (NIH) has granted the company a licence to a vaccine antigen candidate (DS2), designed for use in prophylactic vaccines against Respiratory Syncytial Virus (RSV). RSV is a common contagious virus affecting the lungs and breathing passages which causes an estimated… The post Vaxxas licenses RSV vaccine candidate appeared first on Australian Manufacturing Forum.
NEW YORK--(BUSINESS WIRE) October 22, 2024 -- Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved...
HONG KONG SAR - Media OutReach Newswire - 30 October 2024 - AIM Vaccine (06660.HK), the leader in Chinese mRNA vaccines, announced on 30th October...
WASHINGTON, USA, (PAHO) – Starting in the first quarter of 2025, the Pan American Health Organization (PAHO), through its Regional Revolving Funds,...
Press Release November 1, 2024 The Department of Health is reminding Nunavummiut that viral respiratory infections are expected to increase as...
Updated Date: Mon, 04 Nov 2024 00:00:00 EST
Updated Date: Mon, 28 Oct 2024 00:00:00 EDT
Free shots that can protect babies from respiratory syncytial virus are being offered by some health-care providers in Ontario and the Northwest...
Free shots that can protect babies from respiratory syncytial virus are being offered by some health-care providers in Ontario and the Northwest...
The health of our children is such a precious thing, so with the increase in respiratory syncytial virus (RSV) infections between November and April,...
By Staff October 23rd, 2024 BURLINGTON, ON Hamilton Health Sciences (HHS) is opening new respiratory syncytial virus (RSV) clinics this fall for...